Skip to main content
Caplight Logo









SphingoTec

SphingoTec

Private
HennigsdorfHealthcare & Life Scienceshttps://www.sphingotec.eu/

Last Round

Series C

Aug 8, 2024

Total Funding Raised

$28.55M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

SphingoTec is a diagnostics company that develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

biomarker assaysnovel biomarkersin-vitro diagnosticsIVDpoint-of-care diagnosticsPOC diagnosticsbiomarker out-licensingacute care diagnosticscritical care diagnosticspenKidsepsis diagnosticsacute kidney injurykidney function assessmentbio-ADMacute heart failureclinical trial supportNexus IB10endothelial function

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SphingoTec Comparables

Compare SphingoTec with similar companies based on industry and business-model similarity.

SphingoTec comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Immunexpress
78%
BioPorto A/S
77%
Inflammatix
72%

SphingoTec Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 8, 2024
VC RoundFeb 21, 2024
Growth EquityOct 8, 2018

SphingoTec Investors

Notable investors and investment history

SphingoTec investors
InvestorRounds
Think.HealthSeries C
HBM Healthcare InvestmentsSeries C, Growth Equity
NRW.BankSeries C
Brandenburg KapitalSeries C
Wellington PartnersSeries C, Growth Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 29, 2026

    Grew 18% QoQ, from 17 to 20 employees.

  • Jan 20, 2026

    Monthly visitors grew 263% MoM, reaching 2K.

SphingoTec Filings

Explore SEC and related filing metadata, where available.

SphingoTec filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SphingoTec's valuation, stock price, and market status.

Is SphingoTec a public or private company?

SphingoTec is a private company.

What is the current stock price of SphingoTec?

SphingoTec is a private company with no public stock price. No recent secondary market data is available.

How much is SphingoTec worth (valuation)?

Valuation information for SphingoTec is not publicly available.

Can I buy SphingoTec stock?

SphingoTec shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SphingoTec's last funding round?

SphingoTec's most recent funding round was Series C on August 8, 2024.

Who are the main investors in SphingoTec?

Key investors in SphingoTec include Think.Health, HBM Healthcare Investments, Wellington Partners.

Will SphingoTec IPO soon?

No public IPO plans have been announced for SphingoTec.

How can I track SphingoTec secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SphingoTec's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHennigsdorf
Employee Range14
Year Founded2002
Last FundingAug 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?